Section Arrow
Quote
LTGO.NASDAQ
- Latigo Biotherapeutics, Inc.
Quotes are at least 15-min delayed:2026/11/08 16:30 EST
Regular Hours
Last
 12.6
-0.41 (-3.15%)
Day High 
15.95 
Prev. Close
13.01 
1-M High
17.67 
Volume 
556.05K 
Bid
11.05
Ask
14.9
Day Low
12.105 
Open
13.18 
1-M Low
10.24 
Market Cap 
862.55M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.59 
20-SMA 14.94 
50-SMA 18.2 
52-W High 25.93 
52-W Low 10.24 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.85/--
Enterprise Value
862.68M
Balance Sheet
Book Value Per Share
-4.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
KPTIKaryopharm Therapeutics Inc.0.0549-0.0052-8.65%-- 
INOInovio Pharmaceuticals1.215-0.235-16.21%-- 
LABTLakewood-Amedex Biotherapeutics Inc0.3863-0.1543-28.54%-- 
CDTCdt Equity Inc1.31+0.464+54.85%0PE
MRNAModerna254.19+12.73+5.27%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.